BRIEF—Biogen sued by Sage after buyout offer

US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a Bloomberg report.

The lawsuit remains under seal with Delaware’s Chancery Court, the leading US forum for merger fights and corporate cases.

However, a related public filing indicates Sage is seeking an injunction to enforce a standstill agreement against Biogen, its largest shareholder and partner on the postpartum depression drug Zurzuvae (zuranolone).